Published in Drug Discov Today on August 28, 2012
Ivermectin Reproposing for Mild Stage COVID-19 Outpatients (IVER-Leve) | NCT04784481
Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol (2015) 1.25
Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today (2013) 1.24
DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. Cell Death Dis (2014) 1.05
Network-based analysis of vaccine-related associations reveals consistent knowledge with the vaccine ontology. J Biomed Semantics (2013) 0.91
Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology. BMC Bioinformatics (2016) 0.78
A phenome-guided drug repositioning through a latent variable model. BMC Bioinformatics (2014) 0.78
Deciphering miRNA transcription factor feed-forward loops to identify drug repurposing candidates for cystic fibrosis. Genome Med (2014) 0.77
Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing. Sci Rep (2016) 0.76
Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug repositioning. J Comput Aided Mol Des (2016) 0.76
Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures. PLoS One (2016) 0.76
Drug Signature-based Finding of Additional Clinical Use of LC28-0126 for Neutrophilic Bronchial Asthma. Sci Rep (2015) 0.76
The scoring bias in reverse docking and the score normalization strategy to improve success rate of target fishing. PLoS One (2017) 0.75
Systematic integration of biomedical knowledge prioritizes drugs for repurposing. Elife (2017) 0.75
Drug search for leishmaniasis: a virtual screening approach by grid computing. J Comput Aided Mol Des (2016) 0.75
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
Performance comparison of one-color and two-color platforms within the MicroArray Quality Control (MAQC) project. Nat Biotechnol (2006) 5.92
ISA software suite: supporting standards-compliant experimental annotation and enabling curation at the community level. Bioinformatics (2010) 5.60
Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol (2006) 5.14
Toward interoperable bioscience data. Nat Genet (2012) 4.72
The first RSBI (ISA-TAB) workshop: "can a simple format work for complex studies?". OMICS (2008) 4.15
Cross-platform comparability of microarray technology: intra-platform consistency and appropriate data analysis procedures are essential. BMC Bioinformatics (2005) 3.93
A strategy capitalizing on synergies: the Reporting Structure for Biological Investigation (RSBI) working group. OMICS (2006) 3.51
ArrayTrack--supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. Environ Health Perspect (2003) 3.39
QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies. Expert Rev Mol Diagn (2004) 2.73
Evaluation of external RNA controls for the assessment of microarray performance. Nat Biotechnol (2006) 2.59
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics (2008) 2.54
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38
An atypical melanocytic lesion without genomic abnormalities shows locoregional metastasis. J Cutan Pathol (2012) 2.31
Development of public toxicogenomics software for microarray data management and analysis. Mutat Res (2004) 2.29
Maternal smoking during pregnancy and childhood obesity. Am J Epidemiol (2002) 2.27
Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain. Brain (2011) 2.27
Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol (2006) 2.13
The approach to the patient with a difficult melanocytic lesion. Pathology (2004) 2.12
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11
High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology (2013) 2.02
Microarray scanner calibration curves: characteristics and implications. BMC Bioinformatics (2005) 2.02
Assessing batch effects of genotype calling algorithm BRLMM for the Affymetrix GeneChip Human Mapping 500 K array set using 270 HapMap samples. BMC Bioinformatics (2008) 1.98
Edematous erythema, subcutaneous plaques, and severe pain in the lower extremities in an immunocompromised patient. JAMA (2013) 1.97
Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol (2004) 1.90
Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol (2007) 1.89
Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol (2013) 1.88
Stem cells with neural crest characteristics derived from the bulge region of cultured human hair follicles. J Invest Dermatol (2009) 1.85
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest (2014) 1.81
Childhood obesity is associated with maternal smoking in pregnancy. Eur J Pediatr (2002) 1.77
Prolonged exposure to ketamine increases neurodegeneration in the developing monkey brain. Int J Dev Neurosci (2009) 1.76
Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. J Rheumatol (2013) 1.75
GOFFA: gene ontology for functional analysis--a FDA gene ontology tool for analysis of genomic and proteomic data. BMC Bioinformatics (2006) 1.72
ArrayTrack: an FDA and public genomic tool. Methods Mol Biol (2009) 1.71
Reproducible and reliable microarray results through quality control: good laboratory proficiency and appropriate data analysis practices are essential. Curr Opin Biotechnol (2007) 1.71
DNA microarrays are predictive of cancer prognosis: a re-evaluation. Clin Cancer Res (2010) 1.69
Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of clostridium difficile infections. J Clin Microbiol (2009) 1.67
Comparative toxicogenomic analysis of the hepatotoxic effects of TCDD in Sprague Dawley rats and C57BL/6 mice. Toxicol Sci (2006) 1.67
Routine complete capsular closure during hip arthroscopy. Arthrosc Tech (2013) 1.64
Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol Cell (2012) 1.63
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. Chem Res Toxicol (2003) 1.61
Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents (2009) 1.54
Mining FDA drug labels using an unsupervised learning technique--topic modeling. BMC Bioinformatics (2011) 1.53
Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships. The report and recommendations of ECVAM Workshop 52. Altern Lab Anim (2005) 1.52
Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov (2013) 1.52
Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians. Am J Hum Genet (2012) 1.49
Human dermal stem cells differentiate into functional epidermal melanocytes. J Cell Sci (2010) 1.48
Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res (2011) 1.47
Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cutan Pathol (2005) 1.46
Osteochondral lesions of the talus: effect of defect size and plantarflexion angle on ankle joint stresses. Am J Sports Med (2012) 1.44
A novel mutation within the 2B rod domain of keratin 9 in a Chinese pedigree with epidermolytic palmoplantar keratoderma combined with knuckle pads and camptodactyly. Eur J Dermatol (2011) 1.44
Nitrative and oxidative stress in toxicology and disease. Toxicol Sci (2009) 1.44
Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep (2013) 1.43
FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today (2011) 1.42
Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus. Rheumatol Int (2013) 1.41
Comparing next-generation sequencing and microarray technologies in a toxicological study of the effects of aristolochic acid on rat kidneys. Chem Res Toxicol (2011) 1.41
MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. Int J Clin Exp Pathol (2009) 1.38
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res (2007) 1.37
Technical reproducibility of genotyping SNP arrays used in genome-wide association studies. PLoS One (2012) 1.36
Silver nanoparticle induced blood-brain barrier inflammation and increased permeability in primary rat brain microvessel endothelial cells. Toxicol Sci (2010) 1.35
Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum (2012) 1.34
Potential neurotoxicity of ketamine in the developing rat brain. Toxicol Sci (2009) 1.33
Next-generation sequencing and its applications in molecular diagnostics. Expert Rev Mol Diagn (2011) 1.33
Decision forest: combining the predictions of multiple independent decision tree models. J Chem Inf Comput Sci (2003) 1.32
Prediction of estrogen receptor binding for 58,000 chemicals using an integrated system of a tree-based model with structural alerts. Environ Health Perspect (2002) 1.31
The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol (2009) 1.31
Inhalation anesthetic-induced neuronal damage in the developing rhesus monkey. Neurotoxicol Teratol (2011) 1.30
Phytoestrogens and mycoestrogens bind to the rat uterine estrogen receptor. J Nutr (2002) 1.27
Defining the conditions for the generation of melanocytes from human embryonic stem cells. Stem Cells (2006) 1.27
A novel role of Brg1 in the regulation of SRF/MRTFA-dependent smooth muscle-specific gene expression. J Biol Chem (2007) 1.26
Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Mod Pathol (2005) 1.26
Quality control and quality assessment of data from surface-enhanced laser desorption/ionization (SELDI) time-of flight (TOF) mass spectrometry (MS). BMC Bioinformatics (2005) 1.25